Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott Antonia, Emiliano Calvo|The Lancet Oncology|2016Cited by 1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Soft Tissue SarcomaGeorge D. Demetri, Jeffrey D. Wayne, Scott Antonia et al.|Journal of the National Comprehensive Cancer Network|2010Cited by 167
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Amy Prawira et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140